These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 4251764

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasminogen-plasmin system. 3. Kinetics of plasminogen activation and inhibition of plasminogen-plasmin system by some synthetic inhibitors.
    Iwamoto M, Abiko Y, Shimizu M.
    J Biochem; 1968 Dec; 64(6):759-67. PubMed ID: 4238017
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibitors of fibrinolysis: evidence of some instances of mutual potentiation.
    Coccheri S, De Rosa V.
    J Clin Pathol; 1972 Jul; 25(7):627-8. PubMed ID: 4262716
    [No Abstract] [Full Text] [Related]

  • 7. Studies on the mechanism of action of inhibitors of the fibrinolysin system.
    Ambrus CM, Ambrus JL, Lassman HB, Mink IB.
    Ann N Y Acad Sci; 1968 Jun 28; 146(2):430-47. PubMed ID: 4239437
    [No Abstract] [Full Text] [Related]

  • 8. Comparative activities of amino acid and polypeptide inhibitors on natural and synthetic substrates.
    Skoza L, Tse AO, Semar M, Johnson AJ.
    Ann N Y Acad Sci; 1968 Jun 28; 146(2):659-72. PubMed ID: 4239440
    [No Abstract] [Full Text] [Related]

  • 9. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
    Longstaff C.
    Blood Coagul Fibrinolysis; 1994 Aug 28; 5(4):537-42. PubMed ID: 7531000
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
    Takahashi H, Koike T, Yoshida N, Kitahara O, Hanano M, Shibata A, Aoki N.
    Am J Hematol; 1986 Oct 28; 23(2):153-66. PubMed ID: 2944378
    [Abstract] [Full Text] [Related]

  • 17. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY, Fredenburgh JC, Stewart RJ, Rischke JA, Weitz JI.
    Thromb Haemost; 2001 Mar 28; 85(3):502-8. PubMed ID: 11307822
    [Abstract] [Full Text] [Related]

  • 18. The plasmin-antiplasmin system: structural and functional aspects.
    Schaller J, Gerber SS.
    Cell Mol Life Sci; 2011 Mar 28; 68(5):785-801. PubMed ID: 21136135
    [Abstract] [Full Text] [Related]

  • 19. Fibrinolysis in the first year of life.
    Ekelund H.
    Acta Paediatr Scand; 1972 Jan 28; 61(1):5-10. PubMed ID: 4259706
    [No Abstract] [Full Text] [Related]

  • 20. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR.
    Behring Inst Mitt; 1983 Aug 28; (73):43-55. PubMed ID: 6236789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.